Trial Profile

Dopamine D2 and D3 Receptor Occupancy and Clinical Response in Older Patients With Schizophrenia.

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 18 Sep 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Risperidone (Primary)
Indications Psychotic disorders; Schizoaffective disorder; Schizophrenia
Focus Biomarker; Pharmacokinetics

Most Recent Events

07 Feb 2020 Biomarkers information updated
16 Apr 2012 Planned end date changed from 1 Dec 2011 to 1 Dec 2015 as reported by ClinicalTrials.gov.
11 Oct 2011 Additional lead trial investigator identified as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com